Navigation Links
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Date:1/30/2008

SOMERSET, N.J., Jan. 30 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that 311 evaluable events (patient deaths) have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for the treatment of patients with unresectable malignant mesothelioma. Enrollment in the ONCONASE Phase IIIb clinical trial was closed on Sept. 30, 2007. A total of 428 patients were enrolled in the trial.

In accordance with the statistical plan for the study, the company must wait until 316 evaluable events have occurred to conduct the formal statistical analysis required to complete the final sections of the ONCONASE rolling New Drug Application (NDA). To be considered evaluable, patients must meet all of the eligibility requirements for the study and receive at least one dose of study drug.

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alface
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
7. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
8. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
9. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
10. BioCryst Updates Peramivir Clinical Development Plan
11. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre ... Leesburg, Virginia is the first in Loudoun ... Dr. Susan M. Barnes , Medical Director, ... and husband, Dr. Cole Taylor , are avid scuba divers. ...
(Date:1/14/2014)... January 14, 2014 Equashield ( ... hazardous drugs, today announced that it has achieved ... year.   Equashield,s closed systems reduce ... nurses and other medical professionals who prepare and ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to ... much as 50 percent. When coupled with an innovative ... the device facilitated the complete elimination of seizures in ... the decade-long clinical trials. , That,s good news for ... the U.S. living with epilepsy whose seizures can,t be ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... April 22, 2014: The Association for Molecular Pathology ... Journal of Molecular Diagnostics on recommendations for ... and master,s levels of education. The report was ... Task Force of the AMP Training and Education ... need of educating future medical laboratory scientists appropriately ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... Health Organization director-general Dr. Lee Jong-wook dies on 23rd of ... blood clot in his brain//. He was undergoing an emergency ... 61 years old suffered from discomfort while attending an official ... Switzerland for further treatment. ,Lee became WHO director-general ...
... and Women's Hospital (RBWH), Sydney struggles with an outbreak ... wards were found with a bacterium called ... ,To prevent the spread, 12 patients from burns ... were shifted to Sydney hospital and some to Brisbane's ...
... The Union Government may go in for an immunisation campaign ... of measles vaccine. // ,Though the measles vaccines ... the government wants to ensure full coverage through an additional ... told PTI., ,The campaign would commence soon after completion ...
... found that Invitro Fertilization (IVF) resulted in an increase ... is found// that the complication risk is about 16 ... praevia is the common complication found associated with the ... the entire cervix, blocking a baby's passage into the ...
... medical students and doctors participated in a rally held ... at the Deputy Commissioner's office//. The participants were from ... College, and junior doctors. The significance of the rally ... regarding the reservation of 27 % of seats in ...
... popular belief that people who have suffered from hardships early ... a new study reports// that they in reality become more ... gullible adults; this was the finding of a new study ... people who suffered from troubled upbringing during childhood did not ...
Cached Medicine News:
System, English (Continental cord), 230 VAC....
Micro-mini fiber optic light....
The Twin Beam lightsource is a standard light source. The Twin Beam contains two 150W, DNF lamps, one primary lamp, the other to serve as a built-in spare lamp. This allows rapid change to the spare ...
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
Medicine Products: